Eli Lilly bought a stake in Protomer Technologies ... Humulin – which launched in 1982 and remains on sale. Insulin products remain a multibillion-dollar business for the company, alongside ...

The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin lispro-based, and insulin glargine brand Basaglar. "Despite technological ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

The Hawkins County Board of Education will consider entering a national lawsuit regarding alleged insulin price fixing that drove up the cost of healthcare nationwide, including health insurance costs ...

Which insulin brands are in shortage and why? Earlier this year, Eli Lilly reported temporary shortages of Humalog and insulin lispro in 10-milliliter vials. The company said new regulations had ...

Sales of Eli Lilly’s diabetes and weight loss drugs fell far ... citing booming demand for its tirzepatide products. In making the latest adjustment, Lilly cited its "prudent" rollout as it ...

Sanofi and Eli Lilly - implemented price cuts of up to 78% for some of their insulin products and expanded discounts offered by patient assistance programs. None of these measures is protected by ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Lilly accused Pivotal Peptides of selling products that claim to contain tirzepatide ... which is also approved to treat type 2 diabetes under the brand name Mounjaro. In its most recent filings ...

Positive Phase 3 data included the 176-week study of tirzepatide showing 94% reduction in the risk of developing type 2 diabetes in adults ... 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE ...